Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT03850353 Not yet recruiting - Dizziness Clinical Trials

Obstructive Sleep Apnea Syndrome (OSAS) and Dizziness

OSASDiz
Start date: April 1, 2019
Phase:
Study type: Observational

A total of 400 participants will be recruited: 200 patients with suspected OSAS will be recruited from the sleep clinic (OSAS group), 100 patients diagnosed with dizziness will be recruited from the ENT clinic (Dizziness group). In addition, 100 patients with no dizziness and no evidence for OSAS will be recruited from both the sleep clinic and the ENT clinic (controls). Informed consents will be completed by all participants. ). In order to assess the effect of treatment of OSAS on dizziness -patients with the diagnosis of OSAS will complete validated questionnaires regarding sleep, dizziness and eustachian tube function 3 months following initiation of treatment with CPAP

NCT ID: NCT03850314 Not yet recruiting - Obesity Clinical Trials

The Effects of Glycine on Atherosclerosis and Metabolic Syndrome-related Parameters.

Start date: March 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The current study will test the central hypothesis that Glycine supplementation in humans improves Lipid profile and therefore reduces the risk of Atherosclerosis. Secondary outcomes including Insulin sensitivity and parameters related to Metabolic Syndrome (MetS) will also be measured. Furthermore, a mechanistic study in an ex-vivo model will test the hypothesis that Glycine via its key biosynthetic pathway involving Serine Hydroxymethyltransferase 2 (SHMT2), is athero-protective by inhibiting Sterol regulatory element-binding protein 2 (SREBP2)-mediated cholesterol biosynthesis in murine macrophage-like cell line.

NCT ID: NCT03849001 Withdrawn - Multiple Sclerosis Clinical Trials

Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the impact of acute leg cycling conditions at three different intensities versus a control condition condition on symptoms of restless legs syndrome (RLS) in persons with multiple sclerosis (MS). This study includes a proposed sample of 24 participants diagnosed with both MS and RLS that will complete four sessions of supervised exercise or rest conditions in the lab, one session per week, over the course of four weeks.

NCT ID: NCT03848832 Terminated - Rett Syndrome Clinical Trials

Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

ARCH
Start date: July 29, 2019
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of cannabidiol oral solution (GWP42003-P, CBD-OS) in reducing symptom severity when compared with placebo, in participants with Rett syndrome.

NCT ID: NCT03848481 Active, not recruiting - Clinical trials for Prader-Willi Syndrome

CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)

Start date: November 23, 2020
Phase: Phase 2
Study type: Interventional

This study aims to examine the feasibility and safety of cannabidivarin (CBDV) as a treatment for children and young adults with PWS.

NCT ID: NCT03848442 Completed - Rett Syndrome Clinical Trials

'Uptime' Participation Intervention in Girls and Women With Rett Syndrome

Start date: February 7, 2017
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the feasibility and health-related effects of an individualized 12wk 'uptime' participation intervention in girls and women with Rett syndrome. Girls and women above 5 years of age with Rett syndrome and a confirmed MECP2 mutation will be included. Each individual program focuses on participation in enjoyable activities to promote 'uptime' in home, school/day center and community settings. Primary outcomes are sedentary time and daily steps. Secondary outcomes are gross motor skills, walking capacity, quality of life and participation-level goals. Outcomes are evaluated on four occasions: at baseline and after a 6-week interval, immediately following the 12-week intervention program and 12 weeks after the intervention program.

NCT ID: NCT03847571 Recruiting - Bartter Syndrome Clinical Trials

Acetazolamide (AZ) for Management of Alkalosis in Bartter Syndrome

AZ
Start date: January 10, 2019
Phase:
Study type: Observational

In this prospective controlled cross over clinical trial, the investigators aim to evaluate the efficacy and safety of acetazolamide for the management of metabolic alkalosis in children with Bartter syndrome. Urine and blood electrolytes will be measured before and after acetazolamide treatment. The primary end point is a change in polyuria, hypokalemia, and metabolic alkalosis.

NCT ID: NCT03846076 Completed - Clinical trials for Olfactory Reference Syndrome

Internet Delivered CBT for Olfactory Reference Syndrome

Start date: March 4, 2019
Phase: N/A
Study type: Interventional

The primary aim of the study is to test the feasibility and efficacy of, a manual based, Internet-delivered, cognitive behaviour therapy (CBT) for patients with Olfactory Reference Syndrome (ORS) who live in Sweden. The secondary aim is to investigate smell sensitivity and body odor in these ORS-patients.

NCT ID: NCT03845959 Completed - Syndrome Pain Clinical Trials

A Trial of TD0019 in Treatment of Cervical Scapulohumeral Syndrome

Start date: August 30, 2017
Phase: Phase 2
Study type: Interventional

Cervical scapulohumeral syndrome, which is also called scapulohumeral syndrome or cervical radiculopathy is a group of syndromes related to cervical spine disorders with disfunctional nerves and without inflamation. The physical syndromes vary from neck pain, Sensory Processing Disorder/Movenment Disorder of areas dominated by injured nerves. The hard capsule TD0019 is a product based on the traditional prescription named "Độc hoạt tang ký sinh thang" combined with Nattokinase and the extraction of Salix alba Cortex

NCT ID: NCT03845062 Completed - Clinical trials for Obstructive Sleep Apnea Hypopnea Syndrome

Contribution of Drug Induced Sleep Endoscopy of Pediatric Obstructive Sleep Apnea Hypopnea Syndrome

ESSI
Start date: October 1, 2015
Phase:
Study type: Observational

The role of drug-induced sleep endoscopy (DISE) in the management of obstructive sleep apnea hypopnea syndrome (OSAHS) is not precisely defined for children. The primary objective of this study was to describe the consequences of DISE in the therapeutic management for children with OSAHS. The secondary objectives were to analyze the correlation between the number of obstructive sites found during DISE, the value of apnea-hypopnea index (AHI), and the type of OSAHS.